idkmonitor  (Immundiagnostik AG)


Bioz Verified Symbol Immundiagnostik AG is a verified supplier
Bioz Manufacturer Symbol Immundiagnostik AG manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Immundiagnostik AG idkmonitor
    Idkmonitor, supplied by Immundiagnostik AG, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/idkmonitor/product/Immundiagnostik AG
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    idkmonitor - by Bioz Stars, 2022-05
    94/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Immundiagnostik AG idkmonitorⓡ infliximab drug level enzyme linked immunosorbent assay
    Anti-TNF-α agent trough levels in patients after 1 year of anti-TNF-α therapy. (A) <t>Infliximab</t> and (B) adalimumab. TNF, tumor necrosis factor; AGR, albumin-to-globulin ratio.
    Idkmonitorⓡ Infliximab Drug Level Enzyme Linked Immunosorbent Assay, supplied by Immundiagnostik AG, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/idkmonitorⓡ infliximab drug level enzyme linked immunosorbent assay/product/Immundiagnostik AG
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    idkmonitorⓡ infliximab drug level enzyme linked immunosorbent assay - by Bioz Stars, 2022-05
    94/100 stars
      Buy from Supplier

    Image Search Results


    Anti-TNF-α agent trough levels in patients after 1 year of anti-TNF-α therapy. (A) Infliximab and (B) adalimumab. TNF, tumor necrosis factor; AGR, albumin-to-globulin ratio.

    Journal: Gut and Liver

    Article Title: Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients

    doi: 10.5009/gnl20322

    Figure Lengend Snippet: Anti-TNF-α agent trough levels in patients after 1 year of anti-TNF-α therapy. (A) Infliximab and (B) adalimumab. TNF, tumor necrosis factor; AGR, albumin-to-globulin ratio.

    Article Snippet: ADA was quantified using enzyme-linked immunosorbent assay kits (Matriks Biotek, Ankara, Turkey) at an optical density of 450 nm and TLs of anti-TNF-α were assessed using IDKmonitorⓇ infliximab drug level enzyme-linked immunosorbent assay (Immundiagnostik AG, Bensheim, Germany) for infliximab and SHIKARIⓇ Q-ADA (Matriks Biotek) for adalimumab prior to application of anti-TNF-α administration.

    Techniques: